## Edgar Filing: Chawla Lakhmir S - Form 4

Chawla Lal	khmir S							
Form 4	20 2017							
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMB A OMB Number:	PPROVAL 3235-0287
	this box			,			Expires:	January 31
if no lo subject Section Form 4 Form 5 obligati may co <i>See</i> Ins	to 16. or Filed pu tons Section 17.	rsuant to Sec (a) of the Pul	<b>SECU</b> etion 16(a) of the	L OWNERSHIP exchange Act of 19 y Act of 1935 or S t of 1940	ERSHIP OF Estimate burden l respons Act of 1934,		2005 d average ours per e 0.5	
1(b). (Print or Type	e Responses)							
1. Name and Address of Reporting Person <u>*</u> Chawla Lakhmir S			2. Issuer Name <b>an</b> ymbol A JOLLA PHA O [LJPC]	Issuer				
(Last) (First) (Middle) C/O LA JOLLA PHARMACEUTICAL COMPANY,, 4550 TOWNE CENTRE COURT			Date of Earliest 7 Aonth/Day/Year) 2/27/2017		Director 10% Owner X_ Officer (give title Other (specify below) Chief Medical Officer			
			If Amendment, D led(Month/Day/Yea	Applicable I _X_ Form fi	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Table I - Non-	Derivative Secur	ities Acquired, Disp	osed of,	or Beneficia	dly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		3. Transactio Code Year) (Instr. 8)	4. Securities onAcquired (A) or Disposed of (D) (Instr. 3, 4 and 5 (A) or	5. Amount of Securities Beneficially	6. Fc (D (I) (I)	Ownership orm: Direct O) or Indirect	7. Nature of Indirect
Reminder: Ro	eport on a separate lin	e for each class		ficially owned dir Persons wh information required to		form a ne form	ire not 1	SEC 1474 (9-02)

number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

## Edgar Filing: Chawla Lakhmir S - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number 6. Date Exercisable and not Derivative Expiration Date Securities (Month/Day/Year) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. I Der Sec (Ins	
				Code V	(A) (D	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 32.47	12/27/2017		А	6,700	<u>(1)</u>	12/27/2027	Common Stock	6,700	

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
	Director	10% Owner	Officer	Other		
Chawla Lakhmir S C/O LA JOLLA PHARMACEUTICAL COMPANY, 4550 TOWNE CENTRE COURT SAN DIEGO, CA 92121			Chief Medical Officer			
Signatures						
/s/ Ryan Murr, as attorney-in-fact for Lakhmir S. Chawla	12/29	/2017				
**Signature of Reporting Person	Dat	te				

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.